ATE427963T1 - Verfahren, kits und zusammensetzungen zur entwicklung und anwendung von fur antigene niedriger immunogenizitat spezifischen monoklonalen antikírpern - Google Patents

Verfahren, kits und zusammensetzungen zur entwicklung und anwendung von fur antigene niedriger immunogenizitat spezifischen monoklonalen antikírpern

Info

Publication number
ATE427963T1
ATE427963T1 AT04775280T AT04775280T ATE427963T1 AT E427963 T1 ATE427963 T1 AT E427963T1 AT 04775280 T AT04775280 T AT 04775280T AT 04775280 T AT04775280 T AT 04775280T AT E427963 T1 ATE427963 T1 AT E427963T1
Authority
AT
Austria
Prior art keywords
monoclonal antibodies
antigens
antibodies specific
development
kits
Prior art date
Application number
AT04775280T
Other languages
English (en)
Inventor
Vsevolod Ivanovich Kiselev
Petr Georgiyevich Sveshnikov
Original Assignee
Vsevolod Ivanovich Kiselev
Petr Georgiyevich Sveshnikov
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vsevolod Ivanovich Kiselev, Petr Georgiyevich Sveshnikov filed Critical Vsevolod Ivanovich Kiselev
Application granted granted Critical
Publication of ATE427963T1 publication Critical patent/ATE427963T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57575—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/084—Papillomaviridae (F); Polyomaviridae (F), e.g. SV40, BK virus or JC virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2872—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against prion molecules, e.g. CD230
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT04775280T 2003-09-25 2004-09-24 Verfahren, kits und zusammensetzungen zur entwicklung und anwendung von fur antigene niedriger immunogenizitat spezifischen monoklonalen antikírpern ATE427963T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2003128660/15A RU2251699C1 (ru) 2003-09-25 2003-09-25 Способ ранней и доклинической диагностики цервикального рака

Publications (1)

Publication Number Publication Date
ATE427963T1 true ATE427963T1 (de) 2009-04-15

Family

ID=34374510

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04775280T ATE427963T1 (de) 2003-09-25 2004-09-24 Verfahren, kits und zusammensetzungen zur entwicklung und anwendung von fur antigene niedriger immunogenizitat spezifischen monoklonalen antikírpern

Country Status (12)

Country Link
US (1) US20080267982A1 (de)
EP (1) EP1673393B1 (de)
JP (1) JP2007537705A (de)
KR (1) KR20060079239A (de)
CN (1) CN1886425A (de)
AT (1) ATE427963T1 (de)
AU (1) AU2004274368B2 (de)
CA (1) CA2539562A1 (de)
DE (1) DE602004020489D1 (de)
EA (1) EA010506B1 (de)
RU (1) RU2251699C1 (de)
WO (1) WO2005028510A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
JP2006333801A (ja) * 2005-06-03 2006-12-14 Obihiro Univ Of Agriculture & Veterinary Medicine イヌ流産菌およびレプトスピラ菌の検出方法およびそれに用いるプライマーセット
GB0519198D0 (en) * 2005-09-20 2005-10-26 Univ Cambridge Tech Tse detection
US8278056B2 (en) * 2008-06-13 2012-10-02 Oncohealth Corp. Detection of early stages and late stages HPV infection
US8968995B2 (en) 2008-11-12 2015-03-03 Oncohealth Corp. Detection, screening, and diagnosis of HPV-associated cancers
WO2010129821A1 (en) * 2009-05-07 2010-11-11 Oncohealth Corporation Identification of high grade or ≥cin2 for early stages and late stages detection, screening, and diagnosis of human papillomavirus (hpv) and hpv-associated cancers
RU2343485C1 (ru) * 2007-06-14 2009-01-10 Государственное образовательное учреждение высшего профессионального образования "Владивостокский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" (ГОУ ВПО ВГМУ Росздрава) Способ диагностики рака шейки матки
RU2379690C1 (ru) * 2008-09-15 2010-01-20 Федеральное государственное учреждение "Уральский научно-исследовательский институт дерматовенерологии и иммунопатологии Федерального агентства по высокотехнологичной медицинской помощи" (ФГУ "УрНИИДВиИ Росмедтехнологий") Способ диагностики папилломавирусной инфекции
PH12012500982A1 (en) * 2009-11-30 2019-07-10 Genentech Inc Antibodies for treating and diagnosing tumors expressing slc34a2 (tat211=seqid2)
JP5819851B2 (ja) * 2010-01-08 2015-11-24 オンコヘルス コーポレーション Ｈｐｖ関連の癌の治療及びスクリーニングのための細胞に基づいた高処理能力ｈｐｖ免疫アッセイ
SMT201700023T1 (it) 2010-08-02 2017-03-08 Regeneron Pharma Topi che producono proteine leganti vl
ME02106B (me) 2011-02-25 2015-10-20 Regeneron Pharma Miševi sa adam6
EP2734231A1 (de) * 2011-07-21 2014-05-28 Biotech Tools S.A. Dosierung von dnak
HUE047278T2 (hu) 2011-08-05 2020-04-28 Regeneron Pharma Humanizált univerzális könnyûláncú egerek
SG11201401181YA (en) 2011-10-17 2014-04-28 Regeneron Pharma Restricted immunoglobulin heavy chain mice
SG10201605675WA (en) 2011-12-20 2016-09-29 Regeneron Pharma Humanized light chain mice
ME03551B (de) 2012-06-12 2020-07-20 Regeneron Pharma Humanisierte nichtmenschliche tiere mit eingeschränkten schwerkettigen immunglobulin-loci
CN102879584A (zh) * 2012-09-26 2013-01-16 中国人民解放军军事医学科学院基础医学研究所 一种人血液hsp70抗体胶体金标检测试纸条及其制备方法
MY178882A (en) 2013-02-20 2020-10-21 Regeneron Pharma Non-human animals with modified immunoglobulin heavy chain sequences
AU2015231025A1 (en) 2014-03-21 2016-09-15 Regeneron Pharmaceuticals, Inc. Vl antigen binding proteins exhibiting distinct binding characteristics
CA3124228C (en) 2014-03-21 2024-05-14 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
CA2979702A1 (en) 2015-03-19 2016-09-22 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
CN113512107A (zh) * 2021-03-13 2021-10-19 杭州市公安局刑事科学技术研究所 一种杀鼠灵完全抗原及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859613A (en) * 1986-11-12 1989-08-22 Lawrence David A Immunoassays for glutathione and antibodies useful therein
DE3722967A1 (de) * 1987-07-11 1989-01-19 Behringwerke Ag Monoklonale antikoerper gegen e7-protein des humanen papillomvirus typ 16, verfahren zu ihrer herstellung sowie ihre verwendung
ES2193133T3 (es) * 1991-07-13 2003-11-01 Dade Behring Marburg Gmbh Uso de peptidos derivados de los genes e6 y e7 de hpv-16 para fines.
DE4224542A1 (de) * 1992-07-24 1994-01-27 Deutsches Krebsforsch Verfahren zur Herstellung von monoklonalen MHC Klasse I-puls-Peptid-restringierten Antikörpern
ES2171454T3 (es) * 1993-06-04 2002-09-16 Whitehead Biomedical Inst Proteinas de estres y sus usos.
RU2164419C2 (ru) * 1994-03-18 2001-03-27 Мириад Дженетикс, Инк. Ген mts, мутации данного гена и способы диагностики злокачественных опухолей с использованием последовательности гена mts
AR004464A1 (es) * 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
US6191255B1 (en) * 1995-07-14 2001-02-20 Fuji Yakuhin Kogyo Kabushiki Kaisha Protein and monoclonal antibody specific thereto
JPH0987299A (ja) * 1995-07-14 1997-03-31 Fuji Yakuhin Kogyo Kk Ｍｍｐ−２活性化因子に特異的なモノクローナル抗体
JPH0984589A (ja) * 1995-07-14 1997-03-31 Fuji Yakuhin Kogyo Kk 新規なタンパク質
JP3174492B2 (ja) * 1995-11-09 2001-06-11 富士薬品工業株式会社 ウサギｍｍｐ−３に対するモノクローナル抗体及びそれを用いた免疫学的測定法
US6319503B1 (en) * 1998-02-19 2001-11-20 Proteinix Company Heat shock fusion-based vaccine system
DE19918141A1 (de) * 1999-04-21 2000-10-26 Boehringer Ingelheim Vetmed Verfahren zur Diagnose von übertragbaren Spongiformen Enzephalopathien
US7041807B1 (en) * 1999-06-23 2006-05-09 Caprion Pharmaceuticals, Inc. Antibodies to a YYX epitope of a mammalian prion protein
NZ516240A (en) * 1999-06-23 2005-11-25 Caprion Pharmaceuticals Inc Prion protein peptides and uses thereof
US8128922B2 (en) * 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
US20020192205A1 (en) * 2001-05-11 2002-12-19 Francis Michon Immunogenic compositions of low molecular weight hyaluronic acid and methods to prevent, treat and diagnose infections and diseases caused by group A and group C streptococci

Also Published As

Publication number Publication date
EA200600646A1 (ru) 2006-08-25
WO2005028510A2 (en) 2005-03-31
EP1673393A2 (de) 2006-06-28
EP1673393B1 (de) 2009-04-08
KR20060079239A (ko) 2006-07-05
AU2004274368A1 (en) 2005-03-31
CN1886425A (zh) 2006-12-27
US20080267982A1 (en) 2008-10-30
JP2007537705A (ja) 2007-12-27
EA010506B1 (ru) 2008-10-30
RU2251699C1 (ru) 2005-05-10
CA2539562A1 (en) 2005-03-31
WO2005028510A3 (en) 2005-08-25
DE602004020489D1 (de) 2009-05-20
AU2004274368B2 (en) 2010-06-24

Similar Documents

Publication Publication Date Title
ATE427963T1 (de) Verfahren, kits und zusammensetzungen zur entwicklung und anwendung von fur antigene niedriger immunogenizitat spezifischen monoklonalen antikírpern
EA200501286A1 (ru) МОЛЕКУЛЫ АНТИТЕЛ СО СПЕЦИФИЧНОСТЬЮ К ЧЕЛОВЕЧЕСКОМУ IL-1β
EA200800812A1 (ru) Композиции антитела против cd3
PT1639011E (pt) Anticorpos (dab) de domínio único peguilados
EA201100527A1 (ru) Биологические продукты
PE20071055A1 (es) Anticuerpos anti mn
NZ603619A (en) Antibodies that bind to il-12 and methods of purifying the same
EA201590631A1 (ru) Антигенсвязывающие белки, способные связывать тимусный стромальный лимфопоэтин
ATE507302T1 (de) Verfahren zur antikörpererzeugung
HRP20090228T1 (en) Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
HRP20140419T1 (hr) Molekule za vezanje koje mogu neutralizirati virus bjesnoä†e i njihova uporaba
BRPI0407833A (pt) anticorpo monoclonal humano isolado, e, método de tratar ou prevenir um distúrbio
BRPI0607486A2 (pt) anticorpo l243 humanizado, anticorpo biespecìfico ou fragmentos de ligação a antìgeno dos mesmos, composição farmacêutica, kit e uso dos referidos anticorpos
DK1414858T3 (da) Kamelid-enkeltkæde-VHH-antistoffer, fremgangsmåde til fremstilling heraf i et pattedyr samt anvendelser heraf
ATE531390T1 (de) Interleukin-15-(il-15-)spezifische menschliche antikörper
RU2014146707A (ru) Антитела против тофацитиниба и их применение для лекарственного мониторинга
TW200626614A (en) Human monoclonal antibodies to influenza M2 protein and methods of making and using same
TW200732346A (en) Chimeric hepatitis C virus antigens for eliciting an immune response
DE60129278D1 (de) Gegen das SEMP1-Protein gerichtete Antikörper, Verfahren zu deren Herstellung, und deren Anwendungen
FI20011671A7 (fi) Tuumorispesifiset oligosakkaridisekvenssit ja niiden käyttö
DE60234015D1 (de) Latentes tuberkulose-diagnostisches antigen und verwendungsmethode
EP1411962A4 (de) Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper
MX2025012641A (es) Anticuerpo anti-ptk7 y usos del mismo
DE60216906D1 (de) Anti-pilyrosporum ovale igy und dessen verwendung
AR127273A1 (es) Anticuerpos biespecíficos que se unen específicamente a cd47 y her2 y usos de los mismos

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties